News | Heart Failure | July 06, 2015

DC Devices Completes Enrollment In Clinical Trial of InterAtrial Shunt Device for Heart Failure

Company also announces name change to Corvia Medical

Corvia Medical, IASD, REDUCE LAP-HF, InterAtrial Shunt Device, heart failure

July 6, 2015 - DC Devices Inc. announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD). The IASD is a transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF).

The company also announced that it has changed its name to Corvia Medical, Inc.

The REDUCE LAP-HF trial is designed to evaluate the safety and performance of the IASD System in the treatment of heart failure for patients with preserved or mildly reduced ejection fraction who have elevated left atrial pressure and remain symptomatic despite appropriate medical management. Sixty-four patients were implanted at 18 centers in 11 countries. The primary safety endpoint is device-related major adverse cardiac cerebrovascular events (MACCE) and systemic embolic events through six months post-implant.

Principal investigator Prof. Chris Hayward, senior staff cardiologist, Heart Failure and Transplant Unit at St. Vincent's Hospital in Sydney, Australia, commented, "We have treated 10 patients with the IASD System and are very pleased with the results. Many of our patients have been able to return to activities they had previously abandoned, with improvement in their exercise capacity and heart failure symptoms."

Co-investigator David Muller, M.D., director of the cardiac catheterization laboratory, St. Vincent's Hospital, Sydney, commented "The system is elegant and I found it extremely easy to use." He continued, "We have seen substantial benefit in individuals who were previously very symptomatic. I look forward to offering this treatment to more of my patients."

The IASD System is designed to reduce pressure in the heart by allowing blood to flow between the left and right atria. During the minimally-invasive catheter-based procedure, an interventional cardiologist places the IASD through a small opening in the atrial septum. After the implant is deployed, a small passage is formed between the left and right atria so blood can flow between the two chambers, potentially lowering pressure in the left atrium, which is intended to reduce the symptoms of heart failure.

For more information: www.corviamedical.com

Related Content

Guideline Adherence, Not Patient Volume, May Be Better Hospital Heart Failure Metric
News | Heart Failure | February 01, 2018
February 1, 2018 –  In evaluating the quality of care given to those hospitalized with...
First-in-Man RenalGuard Studies Show Promise for Heart Failure Patients
News | Heart Failure | January 02, 2018
RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of...
ACC Issues New Guidance to Optimize Heart Failure Treatment
News | Heart Failure | December 22, 2017
December 22, 2017 — To help streamline treatment of patients with...
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure | November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years among U.S. veterans, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.
News | Heart Failure | November 25, 2017
November 25, 2017 — Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years a
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure | November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure | November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure | November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure | October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure | October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Overlay Init